MedTrace Logo

Omega-3 for Peri- and Postmenopausal Depression

NCT00825994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2014-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if an eight-week intervention with omega-3 fatty acids significantly reduces depressive symptoms in symptomatic peri- and postmenopausal women. We hypothesize that an eight-week trial with omega-3 fatty acids promotes significant improvement in depression symptoms in peri- and postmenopausal women.

Conditions

Interventions

DRUG

Omega-3 Fatty Acids

2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Marlene Freeman, MD · Massachusetts General Hospital Perinatal and Reproductive Psychiatry Program

  • Lee S Cohen, MD · Massachusetts General Hospital Perinatal and Reproductive Psychiatry Program

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825994 on ClinicalTrials.gov